Literature DB >> 9429250

In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae.

P C Hannan1, H M Windsor, P H Ripley.   

Abstract

The in vitro activities of valnemulin (Econor) and two other antimicrobial agents were determined against recent field strains of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae using a broth microdilution method. Valnemulin showed exceptional activity against M hyopneumoniae (MIC90 0.0005 microgram ml-1) and M hyosynoviae (MIC range 0.0001 microgram ml-1 to 0.00025 microgram ml-1) field strains. Tiamulin was 100-fold less active (MIC90 0.05 microgram ml-1) and enrofloxacin 20-fold less active (MIC90 0.01 microgram ml-1) than valnemulin against M hyopneumoniae field isolates and 20-fold to 25-fold less active (MIC range 0.0025 microgram ml-1 to 0.005 microgram ml-1) and 400-fold to 500-fold less active (MIC range 0.05 microgram ml-1 to 0.1 microgram ml-1) respectively against M hyosynoviae field isolates. No significant resistance developed to valnemulin or tiamulin in the type strain of M hyopneumoniae (strain J) or in a recent field isolate (MEVT G23) exposed to 10 in vitro passages in broths containing these antibiotics. Only slight resistance to oxytetracycline was observed. High resistance to tylosin developed in both M hyopneumoniae strains within five to seven in vitro passages in tylosin-containing broth. Providing that similar results are obtained in vivo under field conditions, valnemulin may well prove to be effective in the treatment of enzootic pneumonia and acute polyarthritis in pigs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429250     DOI: 10.1016/s0034-5288(97)90010-2

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  14 in total

1.  In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates.

Authors:  J Vicca; T Stakenborg; D Maes; P Butaye; J Peeters; A de Kruif; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Persistence of Mycoplasma hyopneumoniae in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the parC gene.

Authors:  J Le Carrou; M Laurentie; M Kobisch; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Authors:  Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy; Jorgen S Jensen; Yang Liu; Susanne Paukner
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice.

Authors:  Zhibao Chen; Xuemei Zhang; Xiao Chu; Xiaozhe Zhang; Keji Song; Youshuai Jiang; Lu Yu; Xuming Deng
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

6.  Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins.

Authors:  Feifei Sun; Huiyan Zhang; Gerard Bryan Gonzales; Jinhui Zhou; Yi Li; Jinzhen Zhang; Yue Jin; Zhanhui Wang; Yanshen Li; Xingyuan Cao; Suxia Zhang; Shupeng Yang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Chronic bronchitis in immunocompromised patients: association with a novel Mycoplasma species.

Authors:  D Webster; H Windsor; C Ling; D Windsor; D Pitcher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-26       Impact factor: 3.267

8.  Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug.

Authors:  Xinrui Dong; Xueye Shu; Yingnan Wang; Zhaohuan Niu; Shixia Xu; Yue Zhang; Shuchun Zhao
Journal:  J Vet Med Sci       Date:  2017-11-28       Impact factor: 1.267

9.  The immune mechanism of Mycoplasma hyopneumoniae 168 vaccine strain through dendritic cells.

Authors:  Yumeng Shen; Weiwei Hu; Yanna Wei; Zhixin Feng; Qian Yang
Journal:  BMC Vet Res       Date:  2017-09-15       Impact factor: 2.741

10.  Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.

Authors:  Zilong Huang; Chunxiao Mao; Yanzhe Wei; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Huanzhong Ding
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.